ストックスクリーナーアプリを入手
3.19
0.31%
-0.01
アフターアワーズ：
3.23
0.04
+1.25%
前日終値:
$3.20
開ける：
$3.18
24時間の取引高:
3.08M
Relative Volume:
0.85
時価総額：
$1.03B
収益：
$360.78M
当期純損益:
$-23.91M
株価収益率:
-40.85
EPS:
-0.0781
ネットキャッシュフロー:
$13.07M
1週間 パフォーマンス:
+4.93%
1か月 パフォーマンス:
-4.49%
6か月 パフォーマンス:
+17.71%
1年 パフォーマンス:
-41.89%
1日の値動き範囲:
$3.09
$3.205
1週間の範囲:
$3.01
$3.22
52週間の値動き範囲:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Compare MNKD vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.19 | 1.03B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-19 | 開始されました | Chardan Capital Markets | Buy |
| 2026-02-27 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-13 | 開始されました | Leerink Partners | Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-10-10 | 開始されました | Leerink Partners | Outperform |
| 2025-07-16 | 再開されました | H.C. Wainwright | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-10 | 開始されました | Wedbush | Outperform |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-12-19 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-10-10 | 開始されました | Wedbush | Outperform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 開始されました | Oppenheimer | Outperform |
| 2019-10-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 開始されました | BTIG Research | Buy |
| 2019-03-04 | 開始されました | SVB Leerink | Outperform |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2018-02-28 | ダウングレード | Maxim Group | Hold → Sell |
| 2017-11-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-10 | 開始されました | H.C. Wainwright | Buy |
| 2017-10-06 | 繰り返されました | Maxim Group | Buy |
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-05-10 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-05-10 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2016-01-06 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-01-06 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2015-11-04 | ダウングレード | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | ダウングレード | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-05-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 繰り返されました | MLV & Co | Hold |
| 2015-04-16 | 繰り返されました | RBC Capital Mkts | Outperform |
すべてを表示
Mannkind Corp (MNKD) 最新ニュース
Price to earnings forward of MannKind Corporation – SWB:NNFN - TradingView
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - Yahoo Finance
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - TradingView
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - TradingView
Chardan starts coverage of MannKind stock with a USD 10.00 target - AD HOC NEWS
MNKD Reiterated by Cantor Fitzgerald -- Price Target Maintained at $8.00 - GuruFocus
Learn Why The Bull Case For MannKind Stock Could Change Following Outpatient Diuretic Data - Yahoo Finance
MNKD: IPF pipeline advances as ReadyFlow and TYVASO DPI support growth and diversification - TradingView
Chardan initiates MannKind stock coverage with buy rating on pipeline - Investing.com
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
MNKD Initiates Coverage On Chardan Capital -- Price Target Annou - GuruFocus
Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation? - Yahoo Finance
MannKind stock rises 4.54 percent on Nasdaq at EUR 2.81 - ad-hoc-news.de
MannKind CEO to join panel on chronic respirato... - Pluang
MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire Inc.
MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire
MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire
A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein. - Stock Titan
New data supports Furoscix ReadyFlow autoinject... - Pluang
MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026 - Quiver Quantitative
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
MNKD Maintains Buy Rating -- Price Target Lowered to $5.00 by Truist Securities - GuruFocus
MannKind stock weighs 43 percent revenue growth against losses - AD HOC NEWS
Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquid - GuruFocus
MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal - StocksToTrade
MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com
MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com South Africa
Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK - GuruFocus
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Nigeria
Form 4 MannKind Corp For: 28 September By Investing.com - Investing.com Nigeria
Steven Binder sells $128,477 of MannKind (MNKD) stock - Investing.com
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Canada
Form 144 MannKind Corporation For: 25 September - Investing.com India
Form 144 MannKind Corporation For: 25 September By Investing.com - Investing.com Canada
Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. - Stock Titan
Danbury Company Reports Positive Results In Lung Disease Drug Trial - Patch
MannKind Corporation (MNKD) Options ChainYahoo Finance - Yahoo! Finance Canada
MannKind Corporation (MNKD) Stock Analysis: Exploring a 127.68% Potential Upside in the Biotech Space - DirectorsTalk Interviews
MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Stocktwits
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum - TradingView
MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses - Yahoo Finance
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight rating on MannKind stock - investing.com
MNKD Reiterates by Cantor Fitzgerald -- Price Target Maintained at $6.50 - GuruFocus
Mannkind Corp (MNKD) 財務データ
収益
当期純利益
現金流量
EPS
Mannkind Corp (MNKD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| STEVEN BINDER | Director |
Sep 25 '26 |
Proposed Sale |
3.29 |
39,051 |
128,478 |
0 |
| STEVEN BINDER | Director |
Sep 10 '26 |
Proposed Sale |
3.94 |
33,558 |
132,219 |
0 |
| Binder Steven B. | Director |
Sep 10 '26 |
Sale |
3.81 |
33,558 |
127,856 |
752,309 |
| STEVEN BINDER | Director |
Aug 07 '26 |
Proposed Sale |
3.89 |
39,051 |
151,908 |
0 |
| Binder Steven B. | Director |
Aug 07 '26 |
Sale |
4.06 |
39,051 |
158,547 |
785,867 |
| Binder Steven B. | Director |
Jul 17 '26 |
Sale |
4.06 |
52,485 |
213,089 |
824,918 |
| DAVID THOMSON | Officer |
Jul 17 '26 |
Proposed Sale |
4.04 |
24,109 |
97,400 |
0 |
| STEVEN BINDER | Director |
Jul 17 '26 |
Proposed Sale |
4.04 |
52,485 |
212,039 |
0 |
| Thomson David | EVP Genl Counsel & Secretary |
Jul 17 '26 |
Sale |
4.05 |
24,109 |
97,641 |
797,554 |
| Tross Stuart A | Chief People & Workpl Officer |
Jul 15 '26 |
Option Exercise |
0.00 |
93,790 |
0 |
1,123,950 |
2.34%
9.38%
大文字化:
|
ボリューム (24 時間):